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As scientists continue to elucidate differences between the genomes of cells in healthy and diseased 
conditions, therapies get progressively more targeted. The benefits are obvious: increased 
knowledge about disease states, including cancer-associated mutations and drug resistance, leads 
to greater possibilities for early diagnosis and efficient treatment. However, cells exhibit large 
mutational variations, leading to mixed populations of subclones that may respond differently to 
therapeutics and radiation. Although an individual cancer consists of billions of cells, conventional 
DNA sequencing approaches merely generate an "average" of the genomic DNA of most of the 
cells. Detection of rare mutations requires much more sensitive sequencing, but available 
techniques have been unable to sufficiently distinguish true variation from method-related errors. 
Worse yet, they are not just unsatisfactory for the task, they are also exceedingly expensive. 
To overcome these issues, Drs. Michael Schmitt and Jerry Radich from the Clinical Research 
Division teamed up with colleagues at the University of Washington to develop a sequencing 
approach based on a novel technique termed "duplex sequencing". In 2012, Dr. Schmitt published 
findings showing that results could be greatly improved by separately analyzing both strands of the 
DNA molecule. This was in contrast to current technologies, so called next-generation DNA 
sequencing, which look at a single strand, generating an unacceptable amount of technical errors in 
comparison to the rate of low-frequency mutations. Duplex sequencing overcomes those limitations 
by only scoring mutations that appear in the same position in both complementary DNA strands, 
ignoring amplification and sequencing errors found in just one strand. In a follow-up study, the Fred 
Hutch investigators combined this new approach with an iterative capturing method to enrich 
targeted genes by more than a million-fold. The result: jackpot. "Our approach improves the 
accuracy of DNA sequencing by 100,000-fold or more, and allows us to readily identify rare 
mutations that are undetectable by other approaches," Dr. Schmitt said. The technique is described 
in Nature Methods, demonstrating not only high capacity and accuracy, but also scaling ability for 
multiple targets. 
The field of oncology harbors numerous applications for this technique, according to Dr. Schmitt. 
Besides facilitating early cancer diagnosis and design of targeted treatments, another possibility is  
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continuous screening of patients undergoing therapy. "For example, we could monitor for early 
resistance to a drug by monitoring the levels of cancer-associated mutations in blood, and then 
rapidly switch the patient to a new drug before their cancer progresses significantly," Dr. Schmitt 
said. However, there is more good news: the extreme accuracy of the technique allows sequencing 
of sample sizes as small as a single cell. The new technology could therefore be applied in settings 
where only tiny amounts of DNA are available, yet accuracy is critical, such as forensics and studies 
of extinct organisms (paleogenomics). 
Still, the dinosaurs will have to wait. The investigators are currently using the technique for exploring 
drug resistance mutations in blood cancers, and assessing genetic variability within various human 
cancer types. Methods are also under development for identification of occasional cancer cells that 
may persist after conventional treatment. To avoid relapse, patients who have those cells in their 
blood might need further aggressive treatment, whereas those who are free of circulating tumor cells 
could be treated less aggressively, with lower risks of negative side effects. 
The take-home message is clear: finding a needle in a haystack just got a million times easier. 
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Image provided by Dr. Michael Schmitt 
Duplex sequencing (lower panel) efficiently removed background 
errors, revealing a single point mutation that could not be discerned 
using conventional high-throughput sequencing (upper panel). 
 
